scorecardresearch
Follow Us:
Tuesday, August 16, 2022

Moderna aims to price coronavirus vaccine at $50-$60 per course: Report

Moderna's proposed price would apply to the United States and other high-income countries, according to the report.

By: Reuters |
Updated: July 29, 2020 9:36:47 am
Moderna vaccine, moderna vaccine results, coronavirus vaccine, covid cure, covid vaccine, moderna vaccine news, indian express The final price for Moderna’s COVID vaccine has yet to be determined, a person familiar with the discussions told Reuters.

Moderna Inc is planning to price its coronavirus vaccine at $50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc and BioNTech, the Financial Times reported on Tuesday, citing unnamed sources.

Moderna’s proposed price for a two-dose course sold to governments compares with $39 for two doses under a deal that Pfizer Inc and German partner BioNTech struck with the U.S. government.

Industry analysts said Pfizer and BioNTech’s $2 billion deal to cover 50 million patients, which is contingent on an approvable product, would likely pressure other manufacturers to set similar prices.

Moderna’s proposed price would apply to the United States and other high-income countries, according to the report.

Subscriber Only Stories
UPSC Key-August 16, 2022: Why you should read ‘Thucydides’ Trap’ or ‘Oper...Premium
Explained: All about F-INSAS, Nipun mines, LCA — the new systems ha...Premium
The rise of the worker productivity scorePremium
Delhi Confidential: Tiranga selfies campaign a big hit on Independence DayPremium

READ | Covid-19 vaccine tracker, July 29: Pfizer-BioNTech on the heels of Moderna, enters late stage clinical trials

A Moderna spokesperson said the company was in discussions with governments about potential supply of the vaccine, called mRNA-1273, but did not provide any details on pricing “given the confidential nature of the discussions and contracts.”

The final price for Moderna’s COVID vaccine has yet to be determined, a person familiar with the discussions told Reuters.

Advertisement

Pfizer, Moderna and Merck & Co have said they plan to sell their vaccines at a profit, while some drugmakers, including Johnson & Johnson have announced plans to price their vaccines on a not-for-profit basis.

Also read | Why India will remain a central player in the development of vaccines

AstraZeneca Plc agreed to provide the United States 300 million doses of its potential vaccine in exchange for $1.2 billion in upfront funding, which works out to $4 per dose.

Advertisement

The US  government has provided Moderna with nearly $1 billion in funding to support its research and development efforts for its potential COVID-19 vaccine.

READ | Moderna vaccine protects 16 monkeys from coronavirus; 30,000 humans await

The funding is part of “Operation Warp Speed,” an initiative by the Trump administration to hasten the production of an inoculation for COVID-19, which has so far killed around 650,000 people worldwide.

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest Coronavirus Outbreak News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
First published on: 29-07-2020 at 08:08:06 am

Featured Stories

Advertisement
Advertisement
Advertisement
Advertisement